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Aminoacyl-tRNA synthetaseThe use of the yeast model for the study of the molecular and cellular effects of the pathogenic base
substitutions in human mitochondrial tRNA genes has recently been validated by the ﬁnding that the
suppressing factors identiﬁed in yeast (the mitochondrial protein elongation factor EF-Tu and the cognate
aminoacyl-tRNA synthetase) have suppressing activities also in human cells. In this paper we report a
detailed analysis of the cross-suppressing activities of valyl- and leucyl-tRNA synthetases on different tRNA
mutants. Glycerol growth, respiration, Northern analysis consistently show that similar suppressing effects
can be obtained by these two yeast synthetases and by the orthologous human enzymes. As a whole the
present data indicate that the suppression by mt aa-RS is probably not related to the enzyme activities per se,
and may be due to a stabilizing chaperon-like effect of the synthetase molecules on the tRNA structure
altered by the mutations.LAS, mitochondrial encephalo-
S, aminoacyl-tRNA synthetase;
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Mutations in tRNA genes, when localized in positions involved in
themaintenance of the tRNAmolecule cloverleaf structure (see Fig. 1)
and/or functional role, impair tRNA stability or aminoacylation and
hence protein synthesis. More than 130 pathogenetic mutations have
been associated, in humans, with mt tRNA genes (http://www.
mitomap.org) and are known to cause various disorders, especially
neuromuscular and neurodegenerative, but also hearing loss and
metabolic diseases. Most pathogenetic tRNA mutations are hetero-
plasmic, with varying amounts of the mutatedmt DNA present within
each cell. The phenotypic expression is dependent upon the
proportion of mutated and wt mt DNA molecules. Several homo-
plasmic mutations have also been described as pathogenic and are
often associated with variable penetrance of the defects in the
member of the same family. No treatments are currently available for
the vast majority of these chronic progressive disorders and even the
mechanisms causing these pathologies are almost unknown.
To study the molecular basis and cellular aspects of these diseases,
several pathogenic human-equivalent base substitutions have been
introduced into yeast mitochondria by biolistic transformation [1,2];in fact, in Saccharomyces cerevisiae several mutations in mt tRNA
genes produce severe respiration defects but allow viability by
fermentation. Yeast phenotypes have been tested for growth on
glycerol, respiration and Northern analysis of tRNA molecules on
polyacrylamide sequencing gels, with and without deacylation
treatment. Importantly, we demonstrated that the defective pheno-
types of the biolistic mutants could be suppressed by overexpression
of some nuclearly encoded tRNA interactors, such as the cognate aa-RS
and the mt protein elongation factor EF-Tu [1–4]. It was obviously
very important to understand how far the results obtained in yeast
cells, and in particular those on the suppression of defective
phenotypes, could be extended to human cells. In 2008 three
different groups showed that the orthologous human factors EF-Tu
and cognate aa-RS indeed had suppressive effects in human cells
carrying mutations in tRNALeu and tRNAVal mt genes [5–7], thus
strengthening the hypothesis of a potential therapeutic application
of suppressor molecules or their derivatives.
In the present work, we extend our investigation of the mechanism
and speciﬁcity of suppression by yeast and human aa-RSs by showing
that human valyl- and leucyl-tRNA synthetases can suppress the
defective phenotype of a tRNAVal and a tRNALeu yeast mt mutants.
Unexpectedly, suppressions were also obtained with the non cognate
aa-RS.
We also observed by O2 consumption experiments that the Val
C25T mutant has a partially antimycin A-resistant respiration, which
increases when rescued by synthetases, suggesting the possible
presence of a speciﬁcally activated alternative respiratory pathway.
Finally, since previous experiments highlighted that TUF1 (mt
protein synthesis factor) transcription is activated in yeast mt tRNA
Fig. 1. Cloverleaf structures of yeast mt tRNAs. (A) tRNAVal and (B) tRNALeu. The nucleotides conserved between yeast and human are in bold. Arrows indicate the biolistically
inserted mutations.
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(retrograde response) [3], we analysed the level of mt aa-RS transcripts
to understand their possible implications in regulatory aspects.
2. Materials and methods
2.1. Media, and growth conditions
Strains were grown in YP complete medium (1% yeast extract and
1% peptone from Difco) containing 3% glycerol, or 0.25% or 2% glucose.
Minimalmediumwas 0.7% yeast nitrogen base (Difco), 5% ammonium
sulphate and 2% glucose, supplemented with the necessary auxotro-
phic requirements. For solid plates 1.5% agar (Difco) was added to the
above media. Antimycin A 1 μM was added to 0.25% glucose contain-
ing plates for the antimycin A resistance tests.
Respiration studies were performed using a Clark oxygen
electrode (Hansatech Instruments). Large colonies were collected
from minimal medium (to maintain the suppressor plasmid) and
grown for 4 h in fresh 0.25% glucose containing medium.
The presence of mt DNA was controlled by DAPI staining and
respiratory datawere collected onlywhen the culture retained at least
70–80% of stained cells. After centrifugation the pellet, corresponding
approximately to 0.03 g (wet weight), was washed with 1 ml sterile
water, suspended in 1 ml of phosphate buffer 10 mM, pH 7.4,
containing 0.4% glucose, and loaded in the Reaction Vessel of the
previously calibrated Oxygen Electrode Chamber. The endogenous
oxygen consumption was measured for 12 min. After the indicated
times between 1.5 and 5 min (arrows in Fig. 5) antimycin Awas added
in order to have 1 or 2 μM ﬁnal concentrations in the vessel. The
values derived from at least three independent experiments and the
standard deviation calculated for any point varied between 2 and
10 nmol/ml.
2.2. Strains and plasmids
S. cerevisiae strains are the wt MCC123MATa, ade2-1,ura3-52, leu2,
kar1-1, rho+ [8] and the isogenic syn- strains: Leu A14G, Leu C26(25)T,His G51A and Val C25T [1–4]. The mutants were obtained by biolistic
transformation: the tRNA mutations were created by site direct
mutagenesis following the procedure described in Rohou et al. [9] and
details can be found in Feuermann et al. [1] supplementary
information. Cytoductants were originated by crosses as described
in De Luca et al. [2].
The percentages of rho°/rho− cells were determined as previously
reported [2] and found to be much higher in the mutants (25% and
80% for Val C25T and Leu C26(25)T respectively) than in the wt and
suppressed mutant strains (b3%).
Standard protocols [10] were used for Escherichia coli and yeast
transformations as well as plasmid preparations.
The yeast genes coding for aa-RSs used in suppression experi-
ments were cloned in multi-copy vectors: the NAM2 gene was cloned
into pFL44S vector (pNAM2) [11] (kindly provided by Prof. C.
Herbert); the VAS1 gene was cloned into pCM262 (pVAS1) by the
«gap repair» technique [2]. The HTS1 gene with its own promoter was
cloned into the YEp24 (pHTS1) (gift of Prof. G. Fink [12]).
The human VARS2L gene was digested KpnI/NotI from pcDNA5/
FRT/TO (Invitrogen), a kind gift of Prof. R. Lightowlers and ligated into
pYES2 transcription vector under the inducible Gal1 promoter
(pVARS2). The human LARS1 gene was digested BamHI/XbaI from
the pET32 plasmid (a kind gift of Prof S. A. Martinis) and ligated into
the yeast pYES2 transcription vector under the inducible Gal1
promoter (pLARS1).
2.3. DNA and RNA manipulations
All methods for nucleic acid preparations were as described
previously by Francisci et al. [13]. The RNA quantiﬁcation was
obtained spectrophotometrically (O.D. 260 nm), and the integrity
and purity of RNAs were conﬁrmed by visualisation after separation
by electrophoresis on agarose gel.
Mt RNAs were extracted from puriﬁed mitochondria [13] from
cells grown in YP containing 0.25% glucose to retain the majority of
rho+ cells. The percentage of rho−/rho° colonies and the presence of
mt DNA, was always monitored by DAPI staining. For electrophoresis,
1052 A. Montanari et al. / Biochimica et Biophysica Acta 1803 (2010) 1050–1057blotting and hybridization conditions see Francisci et al. [14] and
references therein. Partially denaturing sequencing gels allow to
distinguish a single-base insertion or deletion in tRNAs [10]. In these
gels mutated tRNAs usually have electrophoretic mobility different
fromwt due to structural alterations, while themobility is the same in
completely denaturing gels [14]. These gels allowed also the
separation of acylated and deacylated tRNAs. To deacylate the tRNAs
samples were subjected to alkaline treatment as described in Francisci
et al. [14].
For Northern analyses the tRNAs were identiﬁed by hybridization
with the speciﬁc oligonucleotides LEU-(5' GTAATACATCTTAAGAG-
TATCG 3') and VAL-(5' CTAGATTTAGGAAATATAGGT 3'), 5' labeled as
described by Sambrook et al. [10]. Hybridization signals were
analyzed using a Phosphorimager (Molecular Dynamics).
2.4. RT-PCR analysis
For RT-PCR experiments the total RNA extraction was performed
using phenol method. The RT-PCR technique is sensitive and allows
the study of poorly expressed genes [15,16]. The experimental
procedure was as previously reported in De Luca et al. [3]. In order
to quantify the concentration of DNA target in our samples,
standard curves were constructed using vectors containing the
speciﬁc synthetase gene (described in the plasmid paragraph) and
YEpLAC181 vector containing the RPK1 gene. These plasmids were
carefully quantiﬁed and serial dilutions starting from 1.6×10−2 ng
and ending at 1.6×10−5 ng were used. The samples were prepared
by adding to the cDNA 12.5 μl of the reactionmixture, containing 1×
SensiMixTM SYBR (Quantance, Bioline) and 0.3 mM of the oligonu-
cleotides NAM2+ (5′-TGCAGTGAAAAAATTAATTGC-3′) and NAM2−(5′-
GTCTTAAAATACATTCATTTGG-3′) or HTS1+ (5'-ATGAGGATGTGAG-
GAAAAT-3') and HTS1- (5'-TTTCCTTCAAAGAACCATTT-3’) or VAS1+
(5'-GTTGCAGTTCATCCTGATG-3') and VAS1-(5'-GGGCTGGAGTGATCT-
TAAC-3') or RPK1+ (5′-GTGAAGGCAAGCTTAAAG-3′) and RPK5-(5′-
GATCATCCAGTTCTTGCAG-3′); H2O was added to reach the ﬁnal volume
of 25 μl. Each standard sample was prepared in duplicate. The
unknown samples were prepared in triplicate with 50 ng of cDNA
and the same reaction mixture as the standard samples. Ampliﬁca-
tion was carried out in the iCycler apparatus from Biorad, as follows:
a denaturation step of 10 min at 95 °C, and 35 cycles of 95 °C for 30 s
54 °C for 30 s and 72 °C for 45 s. The reporter signals were analysed
using the iCycler iQ software (BioRad). These values can be translated
into quantitative results by constructing a standard curve with the
standard sample values. A melting curve was obtained after
completion of the cycles to verify the presence of a single amplicon.
The presented RT-PCR results are mean values of at least three
independent experiments.
2.5. In vivo labeling of mitochondrial products
Mitochondrial translation products were labeled in vivo essentially
as described by Douglas et al. [17]. Exponential cells (OD 600 nm
between 0.2 and 0.5) grown overnight in YP media containing 0.25%
glucose were collected, washed twice with sterile water and
suspended in 40 mM Na-phosphate buffer pH 7.4, 0.45% glucose, in
order to have 32.5 mg cells/ml. 0.850 ml of cell suspension was
transferred in a 10-ml tube, containing 0.1 ml cycloheximide (4 mg/ml)
and incubated at 28 °C for 10 min. Labeling of mitochondrial proteins
was started by addition of 4 μl (0.16 mCi) of L35S-methionine
(40 mCi/ml). After 90 min the reaction was stopped adding 0.1 ml
L-methionine (0.2 M). 35S-methionine and cycloheximide were
removed by washing with water; then, the cells were suspended in
1 ml of buffer containing: 1.2 M sorbitol, 50 mM Na-phosphate pH
7.5, 1% β-mercaptoethanol, 0.2% Zymolase 20 T and incubated at
37 °C for 30 min. Protoplasts were collected and suspended in 1 ml of
Lysis buffer (10 mM Tris–acetate pH 7.5, 0.25 M mannitol, 1 mMEDTA pH 7.5). Mitochondria were collected after 20 min of
centrifugation at 13,000 rpm and washed twice with the same
buffer. Mitochondrial proteins were extracted in 50 μl of 5× Laemmli
buffer (0.05 M Tris–HCl pH 6.8, 2% SDS, 0.002 M EDTA pH 6.8, 1% β-
mercaptoethanol, 10% glycerol, 0.1% bromophenol blue). After 2 min
incubation at 90 °C samples were subjected to SDS-polyacrylamide
gel electrophoresis (PAGE) on 12:0.4% acrylamide/bisacryl-amide
gel having dimensions 20 cm×23 cm (0.4 mm thickness). The
electrophoresis conditions were 3 h at 30 mA in running buffer
(0.05 M Tris–HCl pH 6.8, 0.1% SDS, EDTA 0.002 M pH 6.8, glycine
0,384 M) until the blue dye was at the bottom of the gel. The gel was
then transferred to 3 MM paper, dried (80 °C for 45 min) and
analyzed by autoradiography.
3. Results
3.1. Effect of suppressors on growth and protein synthesis of mutants
We have previously reported that very severe defects caused in
yeast by the MELAS human equivalent mutations in tRNALeuUUR are
rescued by transforming the cells with multicopy plasmids over-
expressing the wt and the mutated versions of Leu-RS in which the
catalytic activity was strongly reduced [2,3].
The yeast strains used in this paper are Leu C26(25)T mutant,
equivalent to the MELAS m. 3256 CNT, and Val C25T mutant,
equivalent to the homoplasmic m. 1624 CNT causing Leigh syndrome
and encephalopathy with variable penetrance in the members of the
same family [18]. (The yeast tRNALeu numbering differs from the
standard numbering [19] referring to yeast cytoplasmic tRNAPhe,
therefore the latter is reported in parenthesis). Although both
mutations occur at the same position in the cloverleaf tRNA structure,
they were previously shown to produce very different yeast
phenotypes, mirroring the different severity of the defects associated
with the equivalent human mutations [4]. In tRNALeu the MELAS
equivalent substitution at position 25 abolished the growth on
respiratory substrates and determined a high production of rho°
colonies (80%). The same base substitution in tRNAVal resulted only in
a delayed growth when glycerol was used as a unique carbon source
and the production of rho° was 25%. Fig. 2A shows the growth studied
by serial dilutions on glycerol plates at 28 °C, of the Val C25T yeast
mutant, bearing a mutation equivalent to the homoplasmic humanm.
1624 CNT. Plates were incubated for 3 days and showed a growth
defect, which was rescued when the yeast cells were transformed
with multicopy plasmids bearing the VAS1 or the NAM2 genes
encoding the Sc Val-RS and the Sc Leu-RS, respectively. The same
mutant was then transformed with the orthologous human genes
(VARS2 and LARS1 encoding the Hs Val-RS and Hs Leu-RS), and also in
this case the glycerol growth defect was suppressed, even if to a lesser
extent compared to the yeast genes. These results indicate that the
sequences responsible for the suppression are probably conserved in
both Valyl- and Leucyl-RSs yeast and human enzymes. Considering
that synthetases must distinguish among the very similar amino acids
leucine, isoleucine and valine [20], we reasoned that suppressive
abilities might be shared by the Leucyl- and Valyl-RSs.
We then wanted to test the reciprocal possibility of cross-
suppression. Results shown in Fig. 2B were obtained with mutant
Leu C26(25)T bearing the mutation equivalent to the MELAS m. 3256
CNT. The growth on glycerol was completely absent in this latter
mutant even after a longer incubation time (5 days at 28 °C)
compared to the previously described Val C25T mutant. The over-
expression of the same genes mentioned above rescued the defective
phenotype of this mutant.
We also eliminated the possibility that the suppression we
observed in both Val C25T and Leu C26(25)T mutants might be due
to an unspeciﬁc effect of any overexpressed aa-RS; Fig. 2 shows the
absence of suppressive effect obtained when the mutants were
Fig. 2. Suppression of the defective growth phenotype by cognate, non cognate and heterologous synthetases. (A) Growth phenotype of mutant Val C25T (equivalent to the human
mutation m. 1624 CNT). Serial dilutions were observed after 3 days on 3% glycerol plates at 28 °C. WT (MCC123), the isogenic mutant Val C25T and the same mutant transformed
with multicopy vectors bearing the gene coding for S. cerevisiae (Sc) mt valyl-tRNA synthetase (pVAS1), H. sapiens (Hs) mt valyl-tRNA synthetase (pVARS2), Sc mt leucyl-tRNA
synthetase (pNAM2), Hsmt leucyl-tRNA synthetase (pLARS1) and Scmt histidyl-tRNA synthetase (pHTS1) are plated. The suppressive effect was observed also at 37 °C. (B) Growth
phenotype of mutant Leu C26(25)T (equivalent to the humanmutation m. 3256 CNT). Serial dilutions were observed after 5 days on 3% glycerol at 28 °C. WT (MCC123), the isogenic
Leu C26(25)T mutant and the samemutant transformed with vectors bearing the gene coding for Scmt Leu-RS (pNAM2), Hsmt Leu-RS (pLARS1), Scmt Val-RS (pVAS1), Hsmt Val-RS
(pVARS2) and Scmt His-RS (pHTS1) are plated. The same suppression effect was observed also at 37 °C. For the highly respiratory defective mutant Leu C26(25)T wewere obliged to
use a lower dilution and a longer incubation time (5 days).
Fig. 3. Autoradiograph of mitochondrially encoded proteins electrophoresis. [35S]
methionine labelled mt protein extracts (see Materials and methods for details) from
wt (MCC123), from the isogenic mutant Leu C26(25)T and from the same mutant
transformed with the plasmid overexpressing the Sc mt Leu-RS (pNAM2) were grown
in 0.25% glucose containing media and applied to SDS-PAGE gel.
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encoding the unrelated Sc His-RS. The overexpression of His-RS was
successfully used to rescue the defective phenotype of its speciﬁc
tRNA mutant His G51A [3].
The above reported experiments were repeated at 37 °C obtaining
similar results for both mutants (not shown).
Newly synthesized mt DNA-encoded proteins can be speciﬁcally
labeled by incubating cells with [35S]-methionine in the presence of
cycloheximide, which blocks cytosolic protein synthesis [17].
Fig. 3 shows a comparison of the in vivo incorporation of [35S]-
methionine in mt proteins by the wt and the mutant Leu C26(25)T
transformed or not with the plasmid bearing the NAM2 suppressor
gene. Autoradiograph reveals that the mitochondria of the wt and of
the suppressed mutant synthesize all the mitochondrially encoded
polypeptides whereas in the mutant the mt protein synthesis is
defective.
3.2. Molecular effect of suppressor genes (Northern analyses)
Northern analyses had shown that, in both mutants, the mature
mutated tRNA was detectable only when one of the suppressor genes
(TUF1 or the cognate aa-RS) was overexpressed [1,2]. In Fig. 4 the
analyses of mt transcripts extracted in acidic conditions from puriﬁed
mitochondria of the wt, of the mutant and of the suppressed strains
are reported. The mutated tRNAVal is not detectable in the mutant,
while its steady state levels and acylation are restored by over-
expression of yeast VAS1 gene. Suppression can also be obtained by
overexpression of the human VARS2 gene, even if the steady state
level is 5-fold lower, as highlighted by the numbers present under
each slot that refer to quantization by Phoretix analysis. A similar
effect was also obtained in the presence of the non-cognate yeast
NAM2 gene. The overexposed panel shows that acylation is not
impaired in the mutant. It can also be noted that in the control
hybridization performed with a tRNALeu speciﬁc probe on the
transformants overexpressing the NAM2 gene, there is a signiﬁcantlyincreased steady state level of the aminoacylated tRNALeu as
compared to the unacylated one (Fig. 4, panel B). Panel B also
shows that the absence of tRNAVal in the mutant is accompanied by a
three time decrease of tRNALeu, probably due to regulatory events
correlated to a slowing down of the mt protein synthesis of the cells;
this phenomenon has been observed for other tRNA mutants [2]. The
Fig. 4. Northern blot analysis of tRNAVal. Analyses of transcripts extracted from puriﬁed mitochondria of wt (MCC123), the isogenic Val C25T mutant and Val C25T transformed with
plasmids overexpressing the VAS1, VARS2 and NAM2 genes. Total RNAs were extracted under acidic conditions from cells grown in YP medium containing 0.25% glucose at 28 °C.
10 µg for wt and 40 µg for the other samples of total mt RNAs were loaded on partially denaturing 10% polyacrylamide-urea acidic gels. Hybridization was with the 5' end-labeled
tRNAVal-probe (A) or with the 5' end-labeled tRNALeu-probe as control (B). (D) Lanes contain samples deacylated by alkaline treatment. Phoretix analysis values of mutant and
suppressed strains are calculated as percentage of the wt; values are reported under each lane taking into account the different amount of RNAs loaded for wt (10 μg) and for the
other samples (40 μg).
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similar, while the partial decrease in the pNAM2 and pVARS2
suppressed mutant can not be easily explained.3.3. Respiratory phenotypes and regulatory aspects
We compared the oxygen consumption of the wt, of the isogenic
Val C25T mutant and of the suppressed mutant cells grown on 0.25%
glucose containing media. Fig. 5 shows the O2 consumption measured
for mutant Val C25T and for mutant cells transformed with the
plasmids bearing the yeast VAS1 or NAM2, or the human VARS2
suppressor genes. O2 consumption of the wt was almost completely
inhibited by the addition of 1 μM antimycin A (see arrows in Fig. 5)
while the weak respiration of the mutant was largely antimycin A
resistant. No inhibition by antimycin A could be observed in the
suppressed mutant (Fig. 5B). Statistical analyses conﬁrmed the
signiﬁcance of these results. The overexpression of suppressor genes
had no effect on wt cells (not shown). The respiration of the
transformants exceeded that of the wt, but in this case the difference
was not statistically signiﬁcant. The effect of antimycin A on growth
capability was veriﬁed on plates containing 0.25% glucose. Fig. 5C
shows the serial dilutions of the wt, of the Val C25T mutant and of the
mutant transformants bearing the yeast VAS1 or NAM2, or the human
VARS2 suppressor genes. The experiment conﬁrmed that the mutant
cells, suppressed or not, are resistant to antimycin A compared to the
wt cells. Table 1 reports the O2 consumption rate (nmol/min) for
0.03 g of cells.
The results reported in Fig. 5 suggest that the low level of
respiration might produce a regulatory shift towards an alternative
respiration pathway bypassing the cytochrome segment of the
respiratory chain.The existence of regulatory circuits aiming to compensate the
energetic defects in mutants has been previously suggested by the
observation of increased amounts of EF-Tu transcript level in various
mutants defective in mt function (retrograde response) [3]. Now we
have examined by RT-PCR the transcript level of Leucyl- and Histidyl-
RSs (Fig. 6) in the wt and two isogenic tRNA mutants (Leu A14G and
His G51A) [3,4]. For comparison, we also analysed by RT-PCR the
expression level of the RPK1 gene encoding the kinase required for
spindle pole body duplication and spindle checkpoint function; this
protein is known to be constitutively and very poorly expressed [21].
As no signiﬁcant differenceswere detected by RT-PCR in the transcript
level of the RPK1 in the analysed strains, the level of the RPK1
transcript was used as a control to compare our samples to each other,
because even if low, RPK1 transcript level was in a range comparable
to that of our target transcripts.
The results (Fig. 6) show that we indeed found a variability in the
amount of aa-RS transcripts and that the cognate synthetase gene is
overexpressed in the speciﬁc tRNA mutant. We observed a similar
regulatory circuit also for Val C25T mutant; in this case the amount of
Val-RS transcript increased by 100 times as compared to the wt (not
shown).4. Discussion
The use of the yeast model for the study of human mt diseases has
shown the existence of nuclearly encoded suppressor genes, which
can alleviate the respiratory defects due to base substitutions in mt
tRNA genes, both in yeast and in human cells.
In this paper we present results concerning the speciﬁcity of
suppression by mt aa-RSs; this mechanism does not seem to be
related to the enzyme activities per se, and thus we hypothesized that
Fig. 5. Measurements of respiration. (A and B) O2 consumption of the wt (MCC123), of the isogenic Val C25T mutant (before and after addition of antimycin A) and of the same
mutant transformed with plasmids bearing the suppressor VAS1, VARS2 and NAM2 genes (see Materials and methods for details). Arrows indicate the time of the antimycin A
additions (seeMaterials andmethods). Three independent measurements of respiratory capacity weremade. t-Tests were used to determine the signiﬁcance of values (Pb0.05). The
data are reported as O2 nmol/min in Table 1. (C) Serial dilutions of the wt, Val C25T and the mutant transformed with pVAS1, pNAM2 and pVARS2 on agar plates containing 0.25%
glucose and 1 μM antimycin A media.
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parts thereof, on the tRNA structure altered by the mutations.
Aa-RSs are very complex, evolutionarily important enzymes on
whose speciﬁcity the ﬁdelity of protein synthesis is based. The
correctness of this process relies on a number of control points which
are mainly guaranteed by the aa-RSs. The activated aminoacid moves
through the two-step aminoacylation reaction of the aa-RS (with the
formation of aminoacyl-adenylate as intermediate). To maintain the
ﬁdelity in protein synthesis aa-RSmust discriminate amongvery similar
aminoacids and in particular distinguish leucine, isoleucine and valine.
Evolution has driven Leucyl-, Isoleucyl- and Valyl-RSs toward high
ﬁdelity with many checks and balances. The accuracy of aminoacyla-
tion depends on both the speciﬁc recognition of aminoacids during
their activation and editing. This latter reaction, which has been
extensively studied for Leu-RS, implies the pre-transfer editing or
coarse sieve (at the aminoacyl-adenylate level) and/or the post-
transfer editing or ﬁne sieve (at the aminoacyl-tRNA level) [22].Table 1
O2 consumption rate values per minute for 0.03 g of cells.
Strains O2 nmol/min
WT 75.9±3.2
WT+antimycin A
Calculated after the drug addition
0.15±0.09
Val C25T 29.4±1.5
Val C25T+antimycin A
Calculated after the drug addition
10.4±1.7
Val C25T+pVAS1 83±5.0
Val C25T+pVAS1 + antimycin A
Calculated after the drug addition
74±5.2
Val C25T+pVARS2 85±5.3
Val C25T+pVARS2 + antimycin A
Calculated after the drug addition
72±4.3
Val C25T+pNAM2 80±4.8
Val C25T+pNAM2 + antimycin A
Calculated after the drug addition
81±5.6
Fig. 6. Quantiﬁcation of NAM2 and HTS1 transcripts by RT-PCR. Quantiﬁcation of NAM2
transcript (A) and HTS1 transcript (B) as ratio to RPK1, in the wt (MCC123) and the
isogenic derivatives (two mt tRNA mutants, Leu A14G and His G51A). The error
(between 3.02×10−3 and 1.21×10−5 is too small for this scale, suggesting that the
ratio between the two transcripts (NAM2 and RPK1 as well as HTS1 and RPK1) is
constant for each strain. The ratio between RPK1mean value and aa-RS mean value was
used to overcome the variability among samples caused by RNA quality and RNA
quantiﬁcation errors. Data derives from at least three independent experiments.
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aa-RSs; they share conserved regions and sequence motifs HIGH and
KMSKS, part of the ATP-binding site. Furthermore the two aa-RSs
have active sites based on the Rossmann fold [11,22] and are thought
to have evolved from a primitive protein by the addition of editing
domains. Relics of the ancestor protein are still present in Aquifex
aeolicus [20].
A very important point to be remembered is that the yeast Leu-RS
(NAM2 gene) was ﬁrst identiﬁed by Dujardin et al. [23] and Herbert
et al. [24] as a suppressor of BI4 intron splicing defects in S. cerevisiae
and this result ﬁrst suggested the capacity of the Nam2p to recognize a
speciﬁc RNA structure to facilitate the splicing activity.
This result, together with the result obtained for Tyr-RS in
Neurospora crassa [25] also indicated the importance of aa-RSs in
the evolution of protein synthesis from the RNA world, probably by
recruiting to synthetases pre-existing motifs and modules. For this
reason the structure of the Nam2p was studied in great detail and the
region of about 160 aa called CP1 (Connecting Polypeptide 1) was
found to be essential for editing and, at the same time, to play a critical
role in intron splicing. CP1 domain is present in the above mentioned
Leucyl- Isoleucyl- and Valyl-RSs [26].
We have previously shown that the cognate synthetase increases
the steady state levels of the mutated tRNA molecule, thus restoring
mitochondrial protein synthesis wherever deﬁcient [2]; this was
conﬁrmed for mutant Leu C26(25)T by comparing the newly
translated mitochondrial products of the suppressed to the not
suppressedmutant cells (Fig. 3). In this work, we show that, at least as
far as Leucyl- and Valyl-RSs are concerned, a cross-suppressing effect
is present and that both synthetases act by increasing the steady state
levels of the two mutated tRNAs. This suggests that the suppressing
action of aa-RS is likely to be mediated by stabilizing the altered
structure of the mutated tRNA, in a chaperone-like manner. Indeed,
the Northern data on mutant Val C25T transformed with the non
cognate synthetase Leu-RS show that the mutant migrates differently
from the wt, indicating that its structure has been altered by the
mutation. A migration pattern different from the wt has been
previously observed for several tRNA mutants [14]. It might be
determined by alterated post-transcriptional modiﬁcations and/or
parts of the tRNA molecule that have differently folded. In these
experiments the suppressors seem to promote an increase of the
steady-state level of aminoacylated tRNAVal (Fig. 4).
Another unexpected and rather intriguing result we report in Fig. 5
is that the respiration of the mutant Val C25T is largely antimycin A
resistant compared to the wt. We could not test the MELAS equivalent
mutant which does not respire at all. A high level of antimycin A
resistant respiration has been observed in gal- cybrids carrying the m.
1624 CNTmutation in tRNAVal (R. Lightowlers personal communication).
An alternative extramitochondrial respiration, based on plasma-
membrane NADPH oxidase activity, has been observed in several
energy deﬁcient human cells, such as cancerous or hematopoietic
stem cells in whichmitochondrial function is impaired [27,28]. On the
other side in some protists, fungi, higher plants and animal phyla, it
has been shown that an alternative pathway, based on the AOX gene,
can by-pass the cytochrome segment of the respiratory chain allowing
the transfer of the electrons directly from the ubiquinone pool to
oxygen, thus maintaining high ATP level and growth notwithstanding
the inhibition of the cytochrome b by antimycin A [29,30]. However
the AOX gene is not present in humans and in S. cerevisiae; this gene
has been used to compensate cytochrome c oxidase deﬁciencies
[31,32]. Our respiration results (Fig. 5) might suggest that in S.
cerevisiae cells in which the mt protein synthesis is impaired some
regulatory event might take place activating an alternative
respiration.
The data reported in this paper, showing the cross-suppressing
activities of Leu-RS, Val-RS and of the orthologous human enzymes
support the possibility that conserved sequences of the twosynthetases might stabilize the altered structure of the mutated
tRNALeu and tRNAVal. The present data also indicate that the yeast mt
Val-RS is the best suppressor, even on the tRNALeu mutant. VAS1 gene
encodes both the cytoplasmic and mitochondrial forms of Val-RS and
therefore its wide suppressing abilities might correspond to a lower
speciﬁcity.
It should therefore be possible to manipulate the studied
synthetases by sequential deletions and to localize the domain
involved in the tRNA stabilization. These reduced sequences might
be of clinical importance.Acknowledgments
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